Seoulin Bioscience Co.Ltd - Asset Resilience Ratio
Seoulin Bioscience Co.Ltd (038070) has an Asset Resilience Ratio of 20.42% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Seoulin Bioscience Co.Ltd's Asset Resilience Ratio has changed over time. Check Seoulin Bioscience Co.Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Seoulin Bioscience Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Seoulin Bioscience Co.Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩24.26 Billion | 20.42% |
| Total Liquid Assets | ₩24.26 Billion | 20.42% |
Asset Resilience Insights
- Good Liquidity Position: Seoulin Bioscience Co.Ltd maintains a healthy 20.42% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Seoulin Bioscience Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Seoulin Bioscience Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Seoulin Bioscience Co.Ltd (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Seoulin Bioscience Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.42% | ₩24.26 Billion ≈ $16.44 Million |
₩118.80 Billion ≈ $80.51 Million |
-1.59pp |
| 2024-12-31 | 22.02% | ₩22.36 Billion ≈ $15.15 Million |
₩101.52 Billion ≈ $68.80 Million |
-6.79pp |
| 2023-12-31 | 28.81% | ₩32.88 Billion ≈ $22.28 Million |
₩114.10 Billion ≈ $77.32 Million |
-10.33pp |
| 2022-12-31 | 39.14% | ₩52.79 Billion ≈ $35.78 Million |
₩134.87 Billion ≈ $91.40 Million |
-14.52pp |
| 2021-12-31 | 53.66% | ₩73.28 Billion ≈ $49.66 Million |
₩136.57 Billion ≈ $92.55 Million |
+29.56pp |
| 2020-12-31 | 24.10% | ₩18.86 Billion ≈ $12.78 Million |
₩78.25 Billion ≈ $53.03 Million |
-3.21pp |
| 2019-12-31 | 27.30% | ₩22.04 Billion ≈ $14.93 Million |
₩80.71 Billion ≈ $54.69 Million |
+13.63pp |
| 2018-12-31 | 13.68% | ₩9.73 Billion ≈ $6.59 Million |
₩71.11 Billion ≈ $48.19 Million |
-1.55pp |
| 2017-12-31 | 15.23% | ₩10.82 Billion ≈ $7.33 Million |
₩71.04 Billion ≈ $48.14 Million |
-9.54pp |
| 2016-12-31 | 24.77% | ₩16.46 Billion ≈ $11.16 Million |
₩66.47 Billion ≈ $45.05 Million |
-4.59pp |
| 2015-12-31 | 29.36% | ₩19.41 Billion ≈ $13.15 Million |
₩66.10 Billion ≈ $44.80 Million |
-2.45pp |
| 2014-12-31 | 31.81% | ₩19.32 Billion ≈ $13.09 Million |
₩60.72 Billion ≈ $41.15 Million |
-1.62pp |
| 2013-12-31 | 33.44% | ₩20.19 Billion ≈ $13.68 Million |
₩60.39 Billion ≈ $40.92 Million |
-- |
About Seoulin Bioscience Co.Ltd
Seoulin Bioscience Co.,Ltd., a bio healthcare company, provides solutions in life sciences and healthcare primarily in South Korea. The company offers solutions for bio research and production; ecoTree, a SLB-120 instrument which produces slightly acidic electrolyzed water for used in food industry, living, and laboratory; plasma-based medical esthetics; miQ for the diagnosis of dementia; and fun… Read more